Core Viewpoint - The company reported strong financial performance in the first half of 2025, exceeding its earnings forecast, driven by a robust business model and increasing consumer awareness in the beauty and health sectors [1][2] Financial Performance - In H1 2025, the company achieved revenue of 1.459 billion, a year-on-year increase of 28.2%, and an adjusted net profit of 191 million, up 37.8% year-on-year, with an adjusted net profit margin of 13.1%, an increase of 0.9 percentage points year-on-year [1] - The beauty and health services segment generated revenue of 807 million, a year-on-year increase of 29.6% [1] - The medical beauty segment reported revenue of 499 million, a year-on-year increase of 13.0% [1] - The sub-health management services segment saw revenue growth of 107.8%, reaching 154 million [1] Business Model and Growth Drivers - The company's "Double Beauty + Double Health" business model is expected to continue benefiting from the rise in consumer sentiment and women's self-care awareness [1] - The number of direct and franchise stores for beauty and health services reached 238 and 276, respectively, with active membership numbers increasing significantly [1] - The company has received NMPA approvals for multiple Class III medical devices for use in the medical beauty sector since 2025, enhancing its product offerings [1] Strategic Initiatives - The company announced plans to further increase its stake in Nairui'er by 20%, showcasing its strong acquisition and integration capabilities [2] - A capital market value enhancement plan was introduced, focusing on long-term shareholder returns, attracting strategic investors, and implementing equity incentive plans [2] - The company has committed to distributing at least 50% of its annual net profit to dividends over the next three fiscal years [2] Profit Forecast and Valuation - The company maintains its profit forecast, expecting net profits of 320 million, 369 million, and 420 million for 2025-2027 [2] - The target price is set at 37.36 HKD, based on a 25x PE ratio for 2025, reflecting the company's sustainable competitive advantages and clear long-term shareholder return mechanisms [2]

Core Viewpoint - The company reported strong financial performance for 1H2025, with significant revenue and profit growth, driven by robust customer traffic and performance across its three main business segments [1][2][3]. Financial Performance - 1H2025 revenue reached 1.459 billion, a year-on-year increase of 28.2%, with a 3.9% growth when excluding the impact of the acquisition of Nairui [1] - Net profit attributable to the parent company was 156 million, up 34.9% year-on-year [1] - Operating cash flow for 1H2025 was 410 million, reflecting an 84.4% increase year-on-year [1] Business Segment Performance - The three main business segments showed strong growth: - Beauty and wellness services generated 810 million, up 29.6% - Medical beauty services reached 500 million, a 13.0% increase - Sub-health medical services surged to 150 million, a remarkable 107.8% growth [1][2] - Direct sales and franchise models contributed to revenue, with direct sales at 740 million (31.0% growth) and franchise at 70 million (16.2% growth) [1] Customer Engagement - Direct sales stores saw customer traffic of 850,000, a 48.6% increase, and active membership rose to 112,000, up 45.7% [1] - Medical beauty direct stores had customer traffic of 50,000, a 28.0% increase, with active members at 24,000, up 27.6% [2] - Sub-health medical services experienced a customer traffic increase of 75.5% to 19,000, with active members growing 93.4% to 7,014 [2] Store Expansion - As of the end of 1H2025, the total number of stores reached 552, an increase of 143 stores year-on-year [3] - The number of beauty and wellness service direct stores was 238, up 69 stores, while franchise stores also increased by 69 to 276 [3] Profitability - The overall gross margin improved by 2.3 percentage points to 49.3%, with net profit margin increasing by 0.5 percentage points to 10.7% [3] - Gross margins for the three business segments were 42.1% for beauty and wellness, 56.9% for medical beauty, and 63.1% for sub-health services, all showing year-on-year improvements [3] Cost Management - Sales, management, and R&D expense ratios were 17.2%, 16.2%, and 1.4%, respectively, with slight increases attributed to acquisitions and marketing efforts [4] - The company is focusing on both organic growth and acquisitions, with the integration of Nairui showing positive results [4] Future Outlook - The company has raised its net profit forecasts for 2025-2027, reflecting confidence in continued growth and integration success [5] - The business model is evolving, with expectations for significant growth potential in the beauty and medical sectors [5]

Core Viewpoint - The company maintains its profit forecast for 2025-2026, with a target price increase of 8% to HKD 40, indicating a 21% upside potential based on its strong business model and growth opportunities [1] Financial Performance - The company reported 1H25 revenue of RMB 1.46 billion, a year-on-year increase of 28.2%, and a net profit attributable to shareholders of RMB 160 million, up 34.9% [2] - Adjusted net profit reached RMB 190 million, reflecting a 37.8% year-on-year growth, exceeding previous forecasts due to scale effects and operational efficiency improvements [2] Business Segments - Beauty and wellness services generated RMB 810 million in revenue, a 29.6% increase, with direct store traffic rising 48.6% to 850,000 visits [3] - Medical beauty services achieved RMB 500 million in revenue, up 13.0%, with active membership increasing 27.6% to 24,000 [3] - Sub-health medical services saw a remarkable revenue growth of 107.8% to RMB 150 million, with active members increasing 93.4% to 7,014 [3] Margin and Efficiency - The company's gross margin improved by 2.4 percentage points to 49.3% in 1H25, driven by scale effects and the inclusion of higher-margin businesses [4] - The adjusted net profit margin reached a historical high of 13.1%, with a year-on-year increase of 0.9 percentage points [4] Growth Strategy - The company is focused on enhancing operational efficiency and increasing service penetration through digital marketing [4] - It is also exploring acquisition opportunities to boost market share, with recent shareholder structure optimization expected to support long-term growth [4]

Core Viewpoint - Company maintains profit forecasts for 2025-2026, with a target price increase of 8% to HKD 40, indicating a 21% upside potential based on strong business model advantages and growth opportunities [1] Financial Performance - Company reported 1H25 revenue of RMB 1.46 billion, a year-on-year increase of 28.2%; net profit attributable to shareholders reached RMB 160 million, up 34.9%; adjusted net profit was RMB 190 million, reflecting a 37.8% increase, exceeding previous forecasts and expectations due to scale effects and operational efficiency [2] Business Segments - Beauty and wellness services generated RMB 810 million in revenue, a 29.6% increase, with direct store traffic up 48.6% to 850,000 and active membership rising 45.7% to 112,000; medical beauty services revenue was RMB 500 million, up 13.0%, with active members increasing 27.6% to 24,000; sub-health medical services revenue surged 107.8% to RMB 150 million, now accounting for over 10% of total revenue, with active members growing 93.4% to 7,014 [3] - The company expanded its store network, adding 69 direct/franchise beauty and wellness stores to reach 238/276, 3 medical beauty stores to total 27, and 2 sub-health stores to 11 [3] Profitability and Efficiency - Gross margin improved by 2.4 percentage points year-on-year to 49.3%, driven by scale effects that reduced procurement costs and diluted fixed costs; adjusted net profit margin reached a historical high of 13.1%, up 0.9 percentage points year-on-year [4] Growth Outlook - The company is focused on enhancing single-store operational efficiency and increasing value-added service penetration while exploring acquisition opportunities to boost market share; recent shareholder structure optimization is expected to support long-term quality growth [5]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company achieved significant revenue and profit growth in the first half of 2025, with revenue reaching 1.459 billion yuan, a year-on-year increase of 28.2%, and net profit of 156 million yuan, up 34.9% [5] - Operating cash flow for the first half of 2025 was 410 million yuan, reflecting an 84.4% year-on-year increase [5] - The company continues to expand its business model through both organic growth and acquisitions, with the integration of the acquired brand NaiRuiEr showing positive results [10] Revenue Performance - The company’s three main business segments showed strong performance: Beauty and Health Services, Medical Aesthetic Services, and Sub-health Medical Services, with respective revenues of 810 million, 500 million, and 150 million yuan, representing year-on-year growth of 29.6%, 13.0%, and 107.8% [6] - Direct sales and franchise models contributed to revenue growth, with direct sales revenue reaching 740 million yuan, up 31.0% year-on-year, and franchise revenue at 70 million yuan, up 16.2% [6] Customer Engagement - Direct sales stores saw a customer footfall of 850,000, a 48.6% increase year-on-year, and active membership grew to 112,000, up 45.7% [6] - The medical aesthetic segment also showed resilience, with foot traffic of 50,000 and active members of 24,000, reflecting year-on-year growth of 28.0% and 27.6% respectively [6] Business Expansion - The company expanded its sub-health medical services, with foot traffic reaching 19,000, a 75.5% increase, and active members growing by 93.4% [7] - The revenue from the functional medicine segment increased by 122.0% year-on-year, driven by new product lines [7] Profitability - The overall gross margin improved by 2.3 percentage points to 49.3%, and the net profit margin increased by 0.5 percentage points to 10.7% [8] - The gross margins for the three business segments were 42.1%, 56.9%, and 63.1%, with respective year-on-year increases of 1.8, 1.8, and 8.7 percentage points [9] Future Outlook - The company plans to continue its dual strategy of organic growth and acquisitions, with a focus on expanding its beauty and health brand matrix and enhancing its medical services [10] - The forecast for net profit for 2025-2027 has been adjusted upwards to 310 million, 350 million, and 410 million yuan, with corresponding EPS estimates of 1.30, 1.48, and 1.72 yuan [10]

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 37.36 [1][10]. Core Insights - The company reported strong growth in its sub-health management business, with a revenue of HKD 1.459 billion for the first half of 2025, representing a year-on-year increase of 28.2%. The adjusted net profit reached HKD 191 million, up 37.8% year-on-year, with an adjusted net profit margin of 13.1% [6][10]. - The company's "Double Beauty + Double Health" business model is expected to continue benefiting from the rising consumer awareness among women and the emotional value associated with beauty and health [6][10]. - The company has received NMPA approval for several Class III medical devices for use in the medical beauty sector, and ongoing innovations in upstream research and development are expected to enhance the product offerings for downstream leading institutions [6][10]. Financial Performance - For the first half of 2025, the beauty and health services segment generated revenue of HKD 807 million, a year-on-year increase of 29.6%. The number of direct and franchise stores reached 238 and 276, respectively, with active membership in direct stores increasing by 45.7% year-on-year [7]. - The medical beauty segment reported revenue of HKD 499 million, a year-on-year increase of 13.0%, with 27 medical beauty stores and a 27.6% increase in active membership [7]. - The sub-health medical services segment saw revenue growth of 107.8% year-on-year, reaching HKD 154 million, with 11 stores and a 93.4% increase in active membership [7]. Strategic Initiatives - The company has increased its stake in Nairui'er by 20%, which is expected to enhance its market share through effective integration capabilities [8]. - A capital market value enhancement plan was initiated, focusing on long-term shareholder return mechanisms, attracting strategic investors, and implementing equity incentive plans to align management and shareholder interests [9]. Earnings Forecast and Valuation - The company maintains its earnings forecast, expecting net profits of HKD 320 million, HKD 369 million, and HKD 420 million for 2025, 2026, and 2027, respectively. The target price is set at 25x PE for 2025, reflecting the company's sustainable competitive advantages and clear long-term shareholder return mechanisms [10][19].

Core Viewpoint - Meili Tianyuan Medical Health (02373) saw its stock price rise over 5%, reaching a new high of 35.06 HKD, driven by strong financial performance and market sentiment [1] Financial Performance - For the six months ending June 30, 2025, the company reported revenue of 1.459 billion RMB, a year-on-year increase of 28.2% [1] - The profit attributable to the company's owners was 156 million RMB, reflecting a year-on-year growth of 34.9% [1] - Basic earnings per share were reported at 0.68 RMB [1] - Revenue from beauty and health services amounted to 807 million RMB, up 29.6% year-on-year [1] - Revenue from sub-health medical services reached 150 million RMB, showing a significant increase of 107.8% year-on-year [1] Market Position and Strategy - Huatai Securities highlighted that the company's evolving "dual beauty + dual health" business model is expected to benefit from the rising consumer awareness among women regarding self-care [1] - Since 2025, several Class III medical device products have received NMPA approval for use in the medical beauty sector, indicating ongoing innovation and regulatory support [1] - Continuous advancements in upstream research and development, including effective raw materials, photonic instruments, and AI skincare, are anticipated to enhance the product offerings of leading downstream institutions [1] - The firm maintains a buy rating on the stock, reflecting confidence in the company's growth trajectory [1]

Core Viewpoint - Meili Tianyuan Medical Health (02373) has seen a significant stock price increase, reaching a new high of 35.06 HKD, driven by strong financial performance and market sentiment [1] Financial Performance - For the six months ending June 30, 2025, the company reported revenue of 1.459 billion RMB, representing a year-on-year growth of 28.2% [1] - The profit attributable to the company's owners was 156 million RMB, up 34.9% year-on-year, with basic earnings per share of 0.68 RMB [1] - Revenue from beauty and health services amounted to 807 million RMB, reflecting a year-on-year increase of 29.6% [1] - Revenue from sub-health medical services reached 150 million RMB, showing a substantial year-on-year growth of 107.8% [1] Market Trends and Business Model - The company is benefiting from the rising consumer awareness of self-care among women, supported by its evolving "dual beauty + dual health" business model [1] - Since 2025, multiple Class III medical device products have received NMPA approval for use in the medical beauty sector, indicating ongoing innovation and regulatory support [1] - Continuous advancements in upstream research and development, including effective raw materials, photonic instruments, and AI skincare, are expected to enhance the product offerings of leading downstream institutions [1]

Core Viewpoint - The company reported strong financial performance for the first half of 2025, with significant revenue and profit growth, showcasing the effectiveness of its business model and strategic initiatives [1][24]. Financial Performance - Revenue for the first half of 2025 reached 1.46 billion yuan, a year-on-year increase of 28.2% [1] - Net profit rose to 170 million yuan, reflecting a substantial growth of 35.5% year-on-year [1] - Adjusted net profit was 191 million yuan, up 37.8% year-on-year, with an adjusted net profit margin of 13.1%, marking a historical high [1] - Cash and cash-equivalent assets amounted to 2 billion yuan, a 27.5% increase year-on-year, with operating cash flow of 410 million yuan, up 84.4% year-on-year [1] Business Segments - The core beauty and health services generated 810 million yuan in revenue, a 29.6% increase year-on-year, with a gross margin of 42.1% [3] - Medical beauty services achieved revenue of 500 million yuan, a 13.0% increase year-on-year, with a gross margin of 56.9% [5] - The sub-brand for sub-health medical services saw explosive growth, with revenue of 150 million yuan, a 107.8% increase year-on-year, and a gross margin of 63.1% [8] Strategic Initiatives - The company has enhanced its digital marketing and multi-channel operations, with private domain operations contributing over 46% of new memberships [5] - The acquisition of a 90% stake in the brand Nairu has shown significant integration effects, with Nairu's revenue reaching 277 million yuan and an adjusted net profit margin increasing from 6.5% to 10.4% [11] - The opening of a flagship clinic in Guangzhou, covering nearly 5,000 square meters, aims to meet the deep health and wellness needs of customers in the Greater Bay Area [14] Shareholder Structure and Market Value - The company has optimized its shareholder structure, with new significant investors enhancing strategic development [18] - A capital market value enhancement plan has been proposed, including a commitment to distribute at least 50% of annual net profit as dividends over the next three fiscal years [18] - The company's market capitalization has increased by 90% year-to-date, reflecting strong market recognition of its value [18] Business Model - The company has developed a unique "dual beauty + dual health" business model, which integrates beauty and medical services to create a competitive advantage [20] - This model allows for efficient collaboration across business segments, maximizing long-term value for members and addressing high customer acquisition costs [21] - The average annual revenue per direct store has exceeded 10 million yuan, with medical beauty and sub-health services accounting for over 45% of total revenue [22]

智通财经APP讯，美丽田园医疗健康(02373)发布截至2025年6月30日止六个月业绩，收入14.59亿元(人 民币，下同)，同比增长28.2%;公司拥有人应占溢利1.56亿元，同比增长34.9%;每股基本盈利0.68元。 会员数量增长驱动公司收入和利润再创新高。2025年上半年总收入同比增长28.2%。随着收入的稳步提 升，规模效应日益显著，推动毛利率同比提升2.3个百分点，达49.3%。 ...